C225H348N48O68 · 4813 g/mol · PubChem CID 156588324 ↗
Tirzepatide
also known as Mounjaro, Zepbound, LY3298176
First-in-class dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. FDA-approved 2022 for type 2 diabetes (Mounjaro) and 2023 for chronic weight management (Zepbound). The SURMOUNT-1 trial showed 20.9% body-weight reduction at 15 mg/week. [jastreboff-2022]
- Class
- GIP / GLP-1 Dual Receptor Agonist
- Half-life
- ~5 days [fda-zepbound-label-2023]
- Evidence level
- FDA-approved
- Regulatory status
- FDA-approved (US)
At a glance
SQ · Abdomen / thigh / arm · Once weekly
Primary target — GIP receptor (GIPR) + GLP-1 receptor (GLP-1R).
Pathway — Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component) [jastreboff-2022][frias-2018].
Downstream effect — Profound glycemic improvement and weight reduction; cardiometabolic benefits.
Origin — 39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinity.
Feedback intact — Glucose-dependent insulin release preserves physiological feedback.
| Parameter | Value |
|---|---|
| Standard dose (T2D) | 5–15 mg / week [fda-zepbound-label-2023] |
| Standard dose (weight) | 5, 10, or 15 mg / week (titrated) [fda-zepbound-label-2023][jastreboff-2022] |
| Titration schedule | 2.5 mg → +2.5 mg every 4 weeks → 15 mg maxSlower titration mitigates GI side effects. |
| Evidence basis | FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS) [jastreboff-2022][fda-zepbound-label-2023] |
| Duration | Indefinite for chronic indication |
| Reconstitution | Pre-filled commercial pen. Research vial: bacteriostatic water per label. |
| Timing | Once weekly, any time of day |
| Half-life | ~5 days (116 h) [fda-zepbound-label-2023] |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Lab verification
Third-party lab reports tied to batch codes, re-verifiable at the issuing lab. A fact and where to re-check it — never a verdict.
- — MTC personal or family history; MEN2
- — Pregnancy / breastfeeding
- — Hypersensitivity to tirzepatide
- — Severe gastroparesis
- — History of pancreatitis
- — Diabetic retinopathy
- 01Reconstitution / device
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
- 02Injection site
SQ — abdomen, thigh, or upper arm. Rotate weekly.
- 03Timing
Once weekly, same day. Day change allowed if ≥3 days separate doses.
- 04Storage
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
- 05Needle
Pen-supplied. Research vial: 27–31G insulin syringe.
Frequently asked
What is the half-life of Tirzepatide?
The reported half-life of Tirzepatide is ~5 days. [fda-zepbound-label-2023]
Is Tirzepatide FDA-approved?
Yes — Tirzepatide is approved by the US FDA.
Sources
of 45 rendered claims carry a resolvable citation.
- [fda-zepbound-label-2023]ZEPBOUND (tirzepatide) injecti 2023 — ZEPBOUND (tirzepatide) injection prescribing information
fda-label, 2023
FDA-approved for chronic weight management. GIP/GLP-1 dual agonist. - [frias-2018]Frias 2018 — Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Lancet, 2018
Tirzepatide (LY3298176) Phase 2b — first proof of GIP+GLP-1 dual agonism efficacy. - [jastreboff-2022]Jastreboff 2022 — Tirzepatide Once Weekly for the Treatment of Obesity
N Engl J Med, 2022
SURMOUNT-1. 2539 adults, 72 weeks. -20.9% body weight at 15 mg dose.